Development of rapid antigen test prototype for detection of SARS-CoV-2 in saliva samples

Kivrane, Agnija; Igumnova, Viktorija; Liepina, Elza Elizabete; Skrastiņa, Dace; Leončiks, Ainārs; Rudevica, Zanna; Kistkins, Svjatoslavs; Reinis, Aigars; Zilde, Anna; Kazāks, Andris; Ranka, Renāte

doi:10.48101/ujms.v127.8207

Cited by 5 publications

(1 citation statement)

References 18 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, some researchers switched to saliva to reduce the risks of infection for the sampler. Saliva may affect the test due to the sample collection and storage technique, which could have implications for the low sensitivity of the assay [ 115 , 116 ]. These conditions have not yet been analyzed.…”

Section: Lateral Flow Immunoassay Evolution In the Pandemicmentioning

confidence: 99%

Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis

et al. 2022

View full text Add to dashboard Cite

SARS-CoV-2 is an emerging infectious disease of zoonotic origin that caused the coronavirus disease in late 2019 and triggered a pandemic that has severely affected human health and caused millions of deaths. Early and massive diagnosis of SARS-CoV-2 infected patients is the key to preventing the spread of the virus and controlling the outbreak. Lateral flow immunoassays (LFIA) are the simplest biosensors. These devices are clinical diagnostic tools that can detect various analytes, including viruses and antibodies, with high sensitivity and specificity. This review summarizes the advantages, limitations, and evolution of LFIA during the SARS-CoV-2 pandemic and the challenges of improving these diagnostic devices.

show abstract

Section: Lateral Flow Immunoassay Evolution In the Pandemicmentioning

confidence: 99%

Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis

et al. 2022

View full text Add to dashboard Cite

show abstract

High-throughput microbead assay system with a portable, cost-effective Wi-Fi imaging module, and disposable multi-layered microfluidic cartridges for virus and microparticle detection, and tracking

Castro

Sommerhage²,

Khanna

et al. 2023

Biomed Microdevices

View full text Add to dashboard Cite

In recent years biomedical scientific community has been working towards the development of high-throughput devices that allow a reliable, rapid and parallel detection of several strains of virus or microparticles simultaneously. One of the complexities of this problem lies on the rapid prototyping of new devices and wireless rapid detection of small particles and virus alike. By reducing the complexity of microfluidics microfabrication and using economic materials along with makerspace tools (Kundu et al. 2018 ) it is possible to provide an affordable solution to both the problems of high-throughput devices and detection technologies. We present the development of a wireless, standalone device and disposable microfluidics chips that rapidly generate parallel readouts for selected, possible virus variants from a nasal or saliva sample, based on motorized and non-motorized microbeads detection, and imaging processing of the motion tracks of these beads in micrometers. Microbeads and SARS-CoV-2 COVID-19 Delta variant were tested as proof-of-concept for testing the microfluidic cartridges and wireless imaging module. The Microbead Assay (MA) system kit consists of a Wi-Fi readout module, a microfluidic chip, and a sample collection/processing sub-system. Here, we focus on the fabrication and characterization of the microfluidic chip to multiplex various micrometer-sized beads for economic, disposable, and simultaneous detection of up to six different viruses, microparticles or variants in a single test, and data collection using a commercially available, Wi-Fi-capable, and camera integrated device (Fig. 1 ). Supplementary Information The online version contains supplementary material available at 10.1007/s10544-023-00661-3.

show abstract

Development of a nano-bioplatform for SARS-CoV-2 specific antigens detection

Golli

Cavalera

Nardo

et al. 2022

2022 IEEE International Conference on Design &Amp; Test of Integrated Micro &Amp; Nano-Systems (DTS)

View full text Add to dashboard Cite

Lateral Flow Immunoassay (LFIA) has been employed for the development of rapid, low-cost, and relatively simple devices for Covid-19 diagnosis. The proposed approach reports the use of the antibody labeled by Gold nanoparticles for the simultaneous detection of Nucleocapsid protein and Spike protein. A comparison with the results obtained by conventional analytical methods (PCR) has been considered in a significant number of nasopharyngeal swabs; 48 and 26 samples from positive and negative individuals respectively. This research provides the basis for the development of a more efficient antigenic test for SARS-CoV-2 detection as a low-cost and quick pre-screening tool.

show abstract

Development of rapid antigen test prototype for detection of SARS-CoV-2 in saliva samples

Cited by 5 publications

References 18 publications

Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis

Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis

High-throughput microbead assay system with a portable, cost-effective Wi-Fi imaging module, and disposable multi-layered microfluidic cartridges for virus and microparticle detection, and tracking

Development of a nano-bioplatform for SARS-CoV-2 specific antigens detection

Contact Info

Product

Resources

About